In the context of septic shock, current clinical trials involving the use of IFN-γ to enhance immune functions are enrolling patients with mHLA-DR levels below 8,000 AB/C (Ignorant [NCT05843786], Immunosep [NCT04990232]) in accordance with the idea of moving away from a "one size fits all" approach towards a more individualized practice [6, 24]. Here, IFNG is linked to Shock.